Research Article
No access
Published Online: 1 May 2017

Interferon Alpha for the Treatment of Cystoid Macular Edema Associated with Presumed Ocular Tuberculosis

Publication: Journal of Ocular Pharmacology and Therapeutics
Volume 33, Issue Number 4

Abstract

Purpose: To report the efficacy and safety of interferon (IFN) α-2a in patients with cystoid macular edema (CME) associated with presumed ocular tuberculosis (TB).
Methods: We reviewed the clinical records of 5 patients with presumed ocular TB who had been treated with IFN α-2a for recurrent CME during or after completion of anti-tubercular therapy. IFN α-2a was administered at an initial dose of 3 million IU per day and then tapered after the initial response. Treatment efficacy was assessed by central macular thickness (CMT) measurement using spectral-domain optical coherence tomography and visual acuity.
Results: Three patients were men, and 2 were women. Patients were aged between 38 and 66 years. Mean CMT was 483 ± 178.6 μm at baseline, 302.3 ± 56 μm at 1 week, 312.3 ± 49.5 μm at 1 month, and 286.2 ± 31.9 μm at 3 months. Mean LogMAR visual acuity was 0.6 ± 0.4 at baseline, 0.4 ± 0.3 μm at 1 week, 0.3 ± 0.3 at 1 month, and 0.3 ± 0.3 at 3 months. The treatment was interrupted for 10 days because of neutropenia after 2 weeks in 1 patient and discontinued in another after 10 days because of intolerance. Total treatment duration was 3–24 months in the remaining 4 patients.
Conclusion: The present small case series suggests that IFN α-2a may be an effective and safe therapeutic option for CME that is associated with presumed ocular TB.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Okhravi N., and Lightman S. Cystoid macular edema in uveitis. Ocul. Immunol. Inflamm. 11:29–38, 2003.
2.
Ossewaarde-van Norel A., and Rothova A. Clinical review: update on treatment of inflammatory macular edema. Ocul. Immunol. Inflamm. 19:75–83, 2011.
3.
Mackensen F., Heinz C., Becker M.D., and Heilingenhaus A. Intravitreal bevacisumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina. 28:41–45, 2008.
4.
Al-Dhibi H., Hamade I.H., Al-Halafi A., et al. The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema. J. Ophthalmol. 2014:729465, 2014.
5.
Lasave A.F., Zeballos D.G., El-Haig W.M., Diaz-Llopis M., Salom D., and Arevalo J.F. Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul. Immunol. Inflamm. 17:423–430, 2009.
6.
Cordero Coma M., Sobrin L., Onal S., Christen W., and Foster C.S. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 114:1574–1579, 2007.
7.
Missotten T., van Laar J.A., van der Loss T.L., et al. Octreotide long-acting repeatable for the treatment chronic macular edema in uveitis. Am. J. Ophthalmol. 144:838–843, 2007.
8.
Kafkala C., Choi J.Y., Choopong P., and Foster C.S. Octreotide as a treatment for uveitic cystoid macular edema. Arch. Ophthalmol. 124:1353–1355, 2006.
9.
Schaap-Fogler M., Amer R., Frilling R., Priel E., and Kramer M. Anti-TNF alpha agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 252:633–640, 2014.
10.
Markomichelakis N., Delicha E., Masselos S., and Sfikakis P.P. Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet Disease: a pilot study in 15 patients. Am. J. Ophthallmol. 154:534–541, 2012.
11.
Farvardin M., Afarid M., Mehryar M., and Hosseini H. Intravitreal infliximab for the treatment of sight-threatening noninfectious uveitis. Retina. 30:1530–1535, 2010.
12.
Diaz-Llopis M., Salom D., Garcia-de-Vicuna C., et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 119:1575–1581, 2012.
13.
Androudi S., Tsironi E., Kalogeropoulos C., Theodoridou A., and Brazitikos P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 117:1612–1616, 2010.
14.
Qian Z., Fardeau C., Cardoso J.N., Jellab B., Fan X., and LeHoang P. Effect of interferon α2a in cystoid macular edema due to intraocular infection. Eur. J. Ophthalmol. 25:431–436, 2015.
15.
Deuter C.M., Kötter I., Günaydin I., Stübiger N., Doycheva D.G., and Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br. J. Ophthalmol. 93:906–913, 2009.
16.
Deuter C.M., Koetter I., Guenaydin I., Stuebiger N., and Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 26:786–791, 2006.
17.
Butler N.J., Suhler E.B., and Rosenbaum J.T. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul. Immunol. Inflamm. 20:86–90, 2012.
18.
Jabs D.A., Nussenblatt R.B., and Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol. 140:509–516, 2005.
19.
Onal S., Kazokoglu H., Koc A., et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis. Arch. Ophthalmol. 129:288–294, 2011.
20.
Aydınoglu-Candan O., Araz-Ersan B., Gul A., Badur S., and Tugal-Tutkun I. Anti-interferon alpha antibodies and autoantibodies in patients with Behcet's disease uveitis treated with recombinant human interferon alpha-2a. Graefes Arch. Clin. Exp. Ophthalmol. 253:457–465, 2015.
21.
Hasanreisoglu M., Cubuk M.O., Ozdek S., Gurelik G., Aktas Z., and Hasanreisoglu B. Interferon alpha-2a therapy in patients with refractory Behcet uveitis. Ocul. Immunol. Inflamm. 25:71–75, 2017.
22.
Gupta V., Gupta A., and Rao N.A. Intraocular tuberculosis-an update. Surv. Ophthalmol. 52:56–87, 2007.
23.
Biswas J., Madhavan H.N., Gopal L., et al. Intraocular tuberculosis. Clinicopathologic study of five cases. Retina. 15:461–468, 1995.
24.
Giles M.C., and Su T. IFN alpha-2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res. 49:277–288, 1995.
25.
Kötter I., Gunaydin I., Zierhut M., and Stübiger N. The use of Interferon alpha in Behçet disease: review of the literature. Semin. Arthritis Rheum. 33:320–335, 2004.

Information & Authors

Information

Published In

cover image Journal of Ocular Pharmacology and Therapeutics
Journal of Ocular Pharmacology and Therapeutics
Volume 33Issue Number 4May 2017
Pages: 304 - 312
PubMed: 28414561

History

Published in print: May 2017
Published online: 1 May 2017
Published ahead of print: 17 April 2017
Accepted: 6 March 2017
Received: 18 July 2016

Permissions

Request permissions for this article.

Topics

    Authors

    Affiliations

    Merih Oray
    Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
    Sumru Onal
    Department of Ophthalmology, Koc University School of Medicine, Istanbul, Turkey.
    Department of Ophthalmology, V.K. Foundation, American Hospital, Istanbul, Turkey.
    Gunay Uludag
    Department of Ophthalmology, Koc University Hospital, Istanbul, Turkey.
    Aylin Koc Akbay
    Department of Ophthalmology, Koc University Hospital, Istanbul, Turkey.
    Ilknur Tugal-Tutkun
    Department of Ophthalmology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.

    Notes

    Address correspondence to:Prof. Ilknur Tugal-TutkunDepartment of OphthalmologyIstanbul UniversityIstanbul Faculty of Medicine34390 CapaIstanbulTurkey
    E-mail: [email protected]; [email protected]

    Author Disclosure Statement

    No competing financial interests exist. I.T.-T. has received financial support outside the submitted work, including honoraria from Servier, AbbVie, Santen, and Allergan.

    Metrics & Citations

    Metrics

    Citations

    Export citation

    Select the format you want to export the citations of this publication.

    View Options

    Get Access

    Access content

    To read the fulltext, please use one of the options below to sign in or purchase access.

    Society Access

    If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

    Restore your content access

    Enter your email address to restore your content access:

    Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

    View options

    PDF/EPUB

    View PDF/ePub

    Full Text

    View Full Text

    Media

    Figures

    Other

    Tables

    Share

    Share

    Copy the content Link

    Share on social media

    Back to Top